Progress in structure-based drug design against influenza A virus

Expert Opinion on Drug Discovery

Volumn 6, Issue 6, 2011, Pages 619-631

  Du, Qi Shi ^a,b,c   Wei, Hang ^a   Huang, Ri Bo ^a,b   Chou, Kuo Chen ^c  

^a GUANGXI UNIVERSITY   (China)

^b NATIONAL ENGINEERING RESEARCH CENTER FOR NON FOOD BIOREFINERY   (China)

^c GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

allosteric mechanism; drug resistance; H1N1; H5N1; influenza A virus; neuraminidase; oseltamivir; rational drug design

Indexed keywords

1, 4 [4 [(3 (2 AMINO 4 HYDROXY 6 METHYL 5 PYRIMIDINYL) PROPYL]AMINO]PHENYL] 1 CHLORO 3 BUTEN 2 ONE; AMANTADINE; ANTIVIRUS AGENT; DANA; INFLUENZA VIRUS HEMAGGLUTININ; KANAMYCIN C; NCI 0605737; NCI 0605741; NCI 0606258; NCI 0607158; NCI 0608643; NCI 0608650; NCI 0624650; NSC 89853; OSELTAMIVIR; OSELTAMIVIR CH2 DANA; OSELTAMIVIR CH2 OSELTAMIVIR; OSELTAMIVIR CH2 ZANAMIVIR; OSELTAMIVIR O ANAMIVIR; PERAMIVIR; PROTEIN M2; PROTOVERINE; PYRIMIDINE DERIVATIVE; RIMANTADINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ALGORITHM; ALLOSTERISM; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; COMPUTER AIDED DESIGN; COMPUTER MODEL; CONFORMATION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; GENE DELETION; GENE INSERTION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INFLUENZA A; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; MOLECULAR DOCKING; NONHUMAN; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SCORING SYSTEM; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

EID: 79957552693     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.571671     Document Type: Review

References (80)

1. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-6 (Pubitemid 28063376)
2. Zimmer SM, Crevar CJ, Carter DM, et al. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh. PLoS One 2010;5:e11601
3. Maugh TH II. Swine flu danger appears to be ebbing. Los Angeles Times (19 March 2010). Available from: http://articles.latimes.com/2010/mar/19/science/ la-sci-swine-flu20-2010mar20 [Retrieved 20 March 2010]
4. Garcia-Sosa AT, Sild S, Maran U. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model 2008;48:2074-80
5. World-Health-Organization (WHO) WHO declares end of H1N1 pandemic. Available from: http://www.pediatricsupersite.com/view.aspx?rid=67459 [Retrieved 10 August 2010]
6. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. J Am Med Assoc 2006;295:891-4
7. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A (H1N1) viruses isolated worldwide. J Infect Dis 2007;196:249-57 (Pubitemid 47047464)
8. Smith BJ, McKimm-Breshkin JL, McDonald M, et al. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 2002;45:2207-12 (Pubitemid 34525800)
9. Kolocouris N, Zoidis G, Foscolos GB, et al. Design and synthesis of bioactive adamantane spiro heterocycles. Bioorg Med Chem Lett 2007;17:4358-62 (Pubitemid 47021378)
10. Lew W, Chen X, Kim CU. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 2000;7:663-72 (Pubitemid 30396423)
11. Dunn CJ, Goa KL. Zanamivir: a review of its use in influenza. Drugs 1999;58:761-84 (Pubitemid 29520519)
12. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008;451:591-5 (Pubitemid 351186272)
13. Pielak RM, Jason JR, Schnell R, et al. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA 2009;106:7379-84
14. Andreas LB, Eddy MT, Pielak RM, et al. Magic Angle Spinning NMR Investigation of Influenza A M218?60: support for an allosteric mechanism of inhibition. J Am Chem Soc 2010;132:10958-960
15. Huang RB, Du QS, Wang CH, et al. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem Biophys Res Commun 2008;377:1243-47
16. Du QS, Huang RB, Wang CH, et al. Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus. J Theor Biol 2009;259:159-64
17. Wei H, Wang CH, Du QS, et al. Investigation into Adamantane- Based M2 Inhibitors with FB-QSAR. Med Chem 2009;5:305-17
18. World-Health-Organization (WHO). A revision of the system of nomenclature for influenza viruses. WHO Memorandum Bull 1980;58:585-91
19. Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM, editors, In Fields Virology. 4th edition. Lippincott, Williams & Wilkins, Philadelphia, USA; 2001. p. 1533-79
20. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors, In Fields Virology. 4th edition. Lippincott, Williams & Wilkins, Philadelphia, USA; 2001. p. 1487-1532
21. Shirvan AN, Moradi M, Aminian M, et al. Preparation of neuraminidase specific antiserum from the H9N2 subtype of avian influenza virus. Turk J Vet Anim Sci 2007;31:219-23 (Pubitemid 47523334)
22. Mukhtar MM, Rasool ST, Song D, et al. Origin of highly pathogenic H5N1 avian influenza virus in China and genetic characterization of donor and recipient viruses. J Gen Virol 2007;88:3094-99 (Pubitemid 350131250)
23. Taubenberger JK, Reid AH, Lourens RM, et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005;437:889-93
24. Moscona A. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med 2005;353:2633-6 (Pubitemid 41817709)
25. Dunn CJ, Goa KL, Zanamivir: a review of its use in influenza. Drugs 1999;58:761-84 (Pubitemid 29520519)
26. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008;453:1258-61 (Pubitemid 351913590)
27. Hauge SH, Dudman S, Borgen K, et al. Oseltamivir resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009;15:155-62
28. Moscona A. Global Transmission of oseltamivir-resistant influenza. N Engl J Med 2009;360:953-6
29. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183:523-31 (Pubitemid 32147507)
30. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55:15-121
31. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005;49:4515-20 (Pubitemid 41552580)
32. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006;193:760-4
33. Du QS, Arteca GA. Modeling lipophilicity from the distribution of electrostatic potential on a molecular surface. J Comput-Aided Mol Des 1996;10:133-9
34. Du QS, Arteca GA. Derivation of fused-sphere molecular surfaces from the electrostatic potential distribution. J Comput Chem 1996;17:1258-68 (Pubitemid 126562031)
35. Du QS, Arteca GA, Mezey PG. Heuristic molecular lipophilicity potential for computer-aided rational drug design. J Comput-Aided Mol Des 1997;11:503-15 (Pubitemid 127505901)
36. Du QS, Mezey PG. Heuristic molecular lipophilicity potential for computer-aided rational drug design: optimizations of screening functions and parameters. J Comput-Aided Mol Des 1998;12:451-71
37. Du QS, Liu PJ, Mezey P. Theoretical derivation of heuristic molecular lipophilicity potential: a quantum chemical description for molecular solvation. J Chem Inf Model 2005;45:347-53 (Pubitemid 40635341)
38. Du QS, Li DP, He WZ, Chou KC. Heuristic molecular lipophilicity potential (HMLP): lipophilicity and hydrophilicity of amino acid side chains. J Comput Chem 2006;27:685-92
39. Du QS, Huang RB, Chou KC. Advances in visual representations of chemical spaces. Expert Opin Drug Discov 2010;5:513-27
40. Meindl P, Tuppy H. 2-Deoxy-2,3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N- acylneuraminic acids. Hoppe Seylers Z Physiol Chem 1969;350:1088-92
41. Meindl P, Bodo G, Palese P, et al. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-Nacetylneuraminic acid. Virology 1974;58:457-63
42. Smith BJ, Colman PM, Von Itzstein M, et al. Analysis of inhibitor binding in influenza virus neuraminidase. Protein Sci 2001;10:689-96 (Pubitemid 32240494)
43. Wang SQ, Du QS, Huang RB, et al. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem Biophys Res Commun 2009;386:432-6
44. Wang SQ, Du QS, Chou KC. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun 2007;354:634-40
45. Du QS, Wang Q, Huanga RB, et al. Computational 3D structures of drug targeting proteins in the 2009-H1N1 influenza A virus. Chem Phys Lett 2010;485:191-5
46. Xu X, Zhu X, Dwek RA, et al. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 2008;82:10493-501
47. Das K, Aramini JM, Ma LC, et al. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 2010;17:530-8
48. Du QS, Wang SQ, Chou KC. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem Biophys Res Commun 2007;362:525-31
49. Wang SQ, Du QS, Chou KC. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun 2007;354:634-40
50. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res 2000;47:1-17 (Pubitemid 30621392)
51. Condra JH, Schleif WA, Blahy OM, et al. Invivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71
52. Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple human-immunodeficiency-virus type-1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994;91:5597-601 (Pubitemid 24174375)
53. Liu HX, Yao XJ, Wang CQ, et al. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Mol Pharm 2010;7:894-904
54. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006;443:45-9 (Pubitemid 44344043)
55. Chen CY. De novo design of novel selective COX-2 inhibitors: from virtual screening to pharmacophore analysis. J Taiwan Inst Chem Eng 2009;40:55-69
56. Chen CY, Huang HJ, Tsai FJ, et al. Drug design for influenza A virus subtype H1N1. J Taiwan Inst Chem Eng 2010;41:8-15
57. Amaro RE, Minh DD, Cheng LS, et al. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 2007;129:7764-65 (Pubitemid 46998169)
58. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42 (Pubitemid 30047768)
59. Kapetanovic IM. Computer-Aided Drug Discovery and Development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 2008;17:165-76
60. Green DV. Virtual screening of virtual libraries. Prog Med Chem 2003;41:61-97 (Pubitemid 137639533)
61. Pozzan A. Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr Pharm Des 2006;12:2099-110 (Pubitemid 43891406)
62. Seifert MH, Kraus J, Kramer B. Virtual high-throughput screening of molecular databases. Curr Opin Drug Discov Devel 2007;10:298-307 (Pubitemid 46800224)
63. An J, Lee DC, Law AH, et al. A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. J Med Chem 2009;52:2667-72
64. Chen CY. Chemoinformatics and pharmacoinformatics approach for exploring the GABA-A agonist from Chinese herb suanzaoren. J Taiwan Inst Chem Eng 2009;40:36-47
65. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-62 (Pubitemid 128590223)
66. Durrant JD, Amaro RE, McCammon JA. AutoGrow: a novel algorithm for protein inhibitor design. Chem Biol Drug Des 2009;73:168-78
67. Kuntz ID, Chen K, Sharp KA, et al. The maximal affinity of ligands. Proc Natl Acad Sci USA 1999;96:9997-10002 (Pubitemid 29422500)
68. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead system. Drug Discov Today 2004;9:430-1 (Pubitemid 38510559)
69. Abad-Zapatero C, Metz JT. Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 2005;10:464-9
70. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-9 (Pubitemid 350273630)
71. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2006;34:668-72
72. von Grotthuss M, Koczyk G, Pas J, et al. Ligand.info 251 small-molecule meta-database. Comb Chem High Throughput Screen 2004;7:757-61
73. Irwin JJ, Shoichet BK. ZINC?A free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177-82
74. Glide, version 4.5; Schrodinger, LLC: New York; 2007
75. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91
76. Wang SQ, Cheng XC, Dong WL, et al. Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. Biochem Biophys Res Commun 2010;401:188-91
77. Du QS, Huang RB, Wang SQ, et al. Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS One 2010;5:e9388
78. Mitrasinovic PM. Advances in the structure-based design of the influenza A Neuraminidase inhibitors. Curr Drug Targets 2010;11:315-26
79. Li Q, Qi JX, Zhang W, et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 2010;17:1266-8
80. Ilyushina NA, Bovin NV, Webster RG, et al. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006;70:121-31 (Pubitemid 43765615)